PCOS and PMOS: understanding the May 2026 name change

The update in plain language

In May 2026, an international consensus process introduced polyendocrine metabolic ovarian syndrome, or PMOS, as the new name for the condition previously called polycystic ovary syndrome, or PCOS. Monash University, which led the process, explains that the new name better reflects the condition’s broader endocrine and metabolic features. This guide keeps PCOS in its publication name because it remains familiar to readers and appears throughout older research. We use PCOS/PMOS when discussing the terminology transition.

Sources for this section: [1] Monash University: May 13, 2026 naming announcement

What changed—and what this update did not do

The terminology note added to the international guideline in 2026 says that the recommendations and content of the 2023 guideline remain unchanged. The next international guideline is planned to use PMOS as its standard terminology. A change in the name is therefore not, by itself, a new treatment recommendation or an instruction to reinterpret an individual diagnosis. It is a reason to recognize both names and ask which guidance a source is using.

Sources for this section: [2] International guideline: 2026 terminology update (PDF)

Why older papers still matter

A paper published before the name change will usually retain its original title. Searching only for PMOS can miss that literature. Conversely, a search using only PCOS may miss newer records that use the new term. Our research desk includes both names. When making a source note, keep the paper’s original title and publication date. You can add the current terminology in your own notes without silently rewriting the source.

A practical example of source labeling

Imagine two saved items: a 2023 guideline carrying PCOS in its title and a 2026 terminology update using PMOS. Do not label them as competing guidelines simply because their names differ. First identify what each document is: a set of clinical recommendations, a terminology statement, a research report or a patient-information page. Then write the question each document answers. The older guideline may address assessment and management; the newer statement may explain naming and implementation. Their roles differ.

Questions for an appointment or a new resource

You can ask, “Do PCOS and PMOS refer to the same condition in this document?” and “Which guideline or criteria are you using?” If a portal, laboratory summary or referral still uses PCOS, the label alone does not tell you whether the care is current. Ask about the content behind the label. This website does not determine whether a person meets diagnostic criteria; its question builder is intended to help you prepare for that discussion.

How this publication handles the transition

We identify the 2026 terminology update, preserve original study titles, and include both names in literature searches. Future articles should distinguish a naming update from a change in evidence or clinical guidance. If you encounter a page that treats the new term as a new disease or implies that the name alone changes someone’s treatment, return to the primary statement and check that claim. Dates and document types are useful parts of a source record.